{"id":904553,"date":"2025-11-03T17:27:29","date_gmt":"2025-11-03T22:27:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-raises-2025-financial-guidance-and-reports-strong-third-quarter-2025-financial-and-operating-results\/"},"modified":"2025-11-03T17:27:29","modified_gmt":"2025-11-03T22:27:29","slug":"halozyme-raises-2025-financial-guidance-and-reports-strong-third-quarter-2025-financial-and-operating-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-raises-2025-financial-guidance-and-reports-strong-third-quarter-2025-financial-and-operating-results\/","title":{"rendered":"HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Royalty Revenue Increased 52%\u00a0YOY to Record $236 million<\/span> and Total Revenue Increased 22% YOY to Record $354 million<\/span><\/i>\n <\/p>\n

\n Net Income Increased 28% YOY to $175 million<\/span>; Adjusted EBITDA Increased 35% YOY to $248 million<\/span>; GAAP Diluted EPS Increased 36% YOY to $1.43<\/span>; Non-GAAP Diluted EPS Increased 35% YOY to $1.72<\/span>1<\/sup><\/i>\n <\/p>\n

\n Raising\u00a02025 Financial Guidance Ranges for Total Revenue to $1,300<\/span> – $1,375 million<\/span>, Representing YOY Growth of 28% – 35%, Adjusted EBITDA to $885<\/span> – $935 million<\/span>, Representing YOY Growth of 40% – 48% and Non-GAAP Diluted EPS to $6.10<\/span> – $6.50<\/span>, Representing YOY Growth of 44% – 54%1<\/sup><\/i>\n <\/p>\n

\n Announces Chief Financial Officer Transition Plan <\/i>\n <\/p>\n

\n
\n SAN DIEGO<\/span>
\n <\/span>, Nov. 3, 2025<\/span><\/span> \/PRNewswire\/ —\u00a0Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme” or the “Company”) today reported its financial and operating results for the third quarter ended September\u00a030, 2025 and provided an update on its recent corporate activities.<\/p>\n

“Halozyme delivered another record quarter, with royalty revenue increasing 52% year-over-year to $236 million<\/span>. This strong performance drove total revenue to a record $354 million<\/span>, representing a 22% increase year-over-year. The continued success of our three established ENHANZE-enabled blockbuster therapies, DARZALEX SC, Phesgo, and VYVGART Hytrulo, highlights the strength of our royalty driven business model. Further expanding our near and long term opportunity, notable achievements this quarter include two new indication approvals: DARZALEX SC for smoldering multiple myeloma in Europe<\/span> and the argenx VYVDURA pre-filled syringe in Japan<\/span> for gMG and CIDP. These events result in achievement to date of 13 of our 15 growth catalysts announced in Q1, which include new product approvals, geographic expansion, and key reimbursement wins across major markets. We project achievement of the two remaining catalysts in Q4. Building on the progress to date, we project the revenue growth contribution of our four additional launched ENHANZE product, Ocrevus Zunuvo, Tecentriq Hybreza, Opdivo Qvantig and Rybrevant SC to increase in 2026 and beyond,” commented Dr. Helen Torley<\/span>, President and CEO of Halozyme.<\/p>\n

“Based on our continued strong performance of our core ENHANZE technology, we are pleased to raise our guidance ranges, with royalty revenue growth of approximately 50% for the full year. As we look ahead, our planned acquisition of Elektrofi represents a significant opportunity to amplify our opportunity in subcutaneous drug delivery by introducing a complementary high-concentration technology that has three large biopharma partner agreements in place. With royalty contributions from Elektrofi’s Hypercon projected to begin in 2030, we are building a multi-platform engine for long-term growth, positioning Halozyme to deliver sustained value for patients, partners, and our shareholders,” said Dr. Torley.<\/p>\n

Halozyme also announced today a transition plan under which Nicole LaBrosse<\/span>, Senior Vice President and Chief Financial Officer (CFO) will continue as CFO until a new Chief Financial Officer is hired, or until March 30, 2026<\/span>, and then, depart to pursue a new professional opportunity. An external search is being initiated to identify the successor.<\/p>\n

“I thank Nicole for her contributions over the past four years as we delivered on our growth strategy,” added Dr. Torley. “We look forward to our next chapter of growth, one in which a diverse range of capital market transactions and M&A will play a key role.”\u00a0<\/p>\n

\n Third Quarter<\/b>
\n \u00a0and Recent Corporate Highlights:<\/b>\n <\/p>\n